Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.
Table of Contents
|2 Framing the Problem||5-16|
|3 Recruitment Challenges in Clinical Trials for Different Diseases and Conditions||17-30|
|4 Models for Public Engagement||31-38|
|5 Messages and Methods for Public Engagement||39-48|
|6 The Media||49-54|
|7 Novel Clinical Trial Designs||55-64|
|8 The Health System's Structure and Culture||65-74|
|9 Toward a Patient-Centered Strategy for Clinical Trials||75-84|
|Appendix A: Workshop Agenda||89-98|
|Appendix B: The Clinical Trials Process||99-100|
|Appendix C: Participant Biographies||101-124|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary...